Merus (NASDAQ: MRUS)
Merus Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Merus Company Info
Merus NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg and Hennie Hoogenboom on June 16, 2003 and is headquartered in Utrecht, the Netherlands.
News & Analysis
Here's Why Merus Stock Is Flying Higher Today
This biotech's second experimental cancer drug to begin clinical trials produced some encouraging results.
4 Stocks Battling Breast Cancer
With Breast Cancer Awareness Month drawing to a close and the San Antonio Breast Cancer Symposium on the horizon, stay alert for breaking news from companies developing new treatments.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.